NASDAQ:TMCI

Treace Medical Concepts (TMCI) Stock Forecast, Price & News

$13.11

+0.91 (+7.46%)

(As of 09/29/2023 ET)

Compare

Today's Range: $12.61
▼
$13.30
50-Day Range: $12.16
▼
$23.26
52-Week Range: $11.85
▼
$27.97

Volume: 762,381 shs
Average Volume: 624,710 shs
Market Capitalization: $806.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.30

Treace Medical Concepts MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 108.2% Upside
$27.30 Price Target
Short Interest: Healthy
3.83% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.74
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.72) to ($0.61) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

355th out of 970 stocks

Surgical & Medical Instruments Industry

46th out of 99 stocks

3.4

Analyst's Opinion

Consensus Rating
Treace Medical Concepts has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.30, Treace Medical Concepts has a forecasted upside of 108.2% from its current price of $13.11.
Amount of Analyst Coverage
Treace Medical Concepts has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.83% of the float of Treace Medical Concepts has been sold short.
Short Interest Ratio / Days to Cover
Treace Medical Concepts has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Treace Medical Concepts has recently increased by 28.68%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Treace Medical Concepts does not currently pay a dividend.
Dividend Growth
Treace Medical Concepts does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TMCI.

2.6

News and Social Media Coverage

News Sentiment
Treace Medical Concepts has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Treace Medical Concepts this week, compared to 2 articles on an average week.
MarketBeat Follows
2 people have added Treace Medical Concepts to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Treace Medical Concepts insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.69% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.85% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Treace Medical Concepts are expected to grow in the coming year, from ($0.72) to ($0.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Treace Medical Concepts is -17.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Treace Medical Concepts is -17.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Treace Medical Concepts has a P/B Ratio of 12.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Treace Medical Concepts (NASDAQ:TMCI) Stock

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision; and Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

TMCI Price History

30 days | 90 days | 365 days | Advanced Chart

TMCI Stock News Headlines

September 29, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Treace Medical Concepts

September 20, 2023 | finance.yahoo.com

Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023

September 30, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

September 17, 2023 | fool.com

Treace Medical Concepts (NASDAQ: TMCI)

September 14, 2023 | finance.yahoo.com

Treace Medical Concepts Announces New Patent Covering Instrumented Bunion Correction Procedures and Milestone 50th U.S. Patent

September 11, 2023 | finance.yahoo.com

Treace Medical Concepts Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related Procedures

August 22, 2023 | finance.yahoo.com

Treace Announces Participation in the 21st Annual Morgan Stanley Global Healthcare Conference

August 21, 2023 | finance.yahoo.com

Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

September 30, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 11, 2023 | nasdaq.com

Stephens & Co. Maintains Treace Medical Concepts (TMCI) Equal-Weight Recommendation

August 10, 2023 | nasdaq.com

Truist Securities Maintains Treace Medical Concepts (TMCI) Buy Recommendation

August 9, 2023 | seekingalpha.com

Treace Medical Concepts Non-GAAP EPS of -$0.20, revenue of $42M

August 9, 2023 | finance.yahoo.com

Treace Medical Concepts Reports Second Quarter 2023 Financial Results

July 24, 2023 | finance.yahoo.com

Treace Announces Participation in the UBS Medtech, Tools and Genomics Summit 2023

July 23, 2023 | markets.businessinsider.com

Treace Medical Concepts (TMCI) Receives a Buy from Truist Financial

July 20, 2023 | msn.com

Treace Medical: New Surgeons, Higher ASPs, And More Lapiplasties: A Positive Trend

July 18, 2023 | finance.yahoo.com

Treace to Report Second Quarter 2023 Financial Results on August 8, 2023

July 12, 2023 | finance.yahoo.com

Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

July 10, 2023 | finance.yahoo.com

While Treace Medical Concepts (NASDAQ:TMCI) shareholders have made 43% in 1 year, increasing losses might now be front of mind as stock sheds 5.0% this week

July 8, 2023 | finance.yahoo.com

TMCI - Treace Medical Concepts, Inc.

June 13, 2023 | finance.yahoo.com

Treace Medical Completes Acquisition of Technology Enabling Patient Specific Instrumentation and Reports on Clinical Cases Using PSI with the Lapiplasty® System

June 5, 2023 | finance.yahoo.com

Treace Medical Concepts, Inc. (NASDAQ:TMCI) is largely controlled by institutional shareholders who own 58% of the company

June 2, 2023 | msn.com

Stephens & Co. Reiterates Treace Medical Concepts (TMCI) Equal-Weight Recommendation

June 2, 2023 | markets.businessinsider.com

BTIG Sticks to Its Buy Rating for Treace Medical Concepts (TMCI)

June 2, 2023 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Treace Medical Concepts

June 1, 2023 | benzinga.com

Treace Medical Concepts to Acquire Technology Enabling Patient Specific Instrumentation for Foot and Ankle Surgeries

June 1, 2023 | msn.com

Treace Medical Concepts buys certain assets of RedPoint Medical3D

See More Headlines

Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

TMCI Company Calendar

Last Earnings: 8/08/2023
Today: 9/30/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TMCI
CUSIP: N/A
CIK: 1630627
Web: www.treace.com
Phone: 904-373-5940
Fax: N/A
Employees: 423
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $27.30
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +108.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.73)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,810,000.00
Net Margins: -25.32%
Pretax Margin: -25.32%
Return on Equity: -39.29%
Return on Assets: -20.76%

Debt

Debt-to-Equity Ratio: 0.35
Current Ratio: 6.60
Quick Ratio: 5.73

Sales & Book Value

Annual Sales: $141.84 million
Price / Sales: 5.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.09 per share
Price / Book: 12.03

Miscellaneous

Outstanding Shares: 61,540,000
Free Float: 43,888,000
Market Cap: $806.79 million
Optionable: Not Optionable
Beta: 0.01

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. John T. Treace (Age 51)
CEO, Founder & Director
Comp: $1.04M

Mr. Mark L. Hair CPA (Age 53)
Chief Financial Officer
Comp: $628.6k

Mr. Aaron J. Berutti (Age 44)
Sr. VP of Sales
Comp: $519.41k

Mr. Terry W. Lubben (Age 58)
Sr. VP of Operations

Ms. Julie D. Dewey (Age 62)
Chief Communications & Investor Relations Officer

Mr. Scot M. Elder (Age 48)
Chief Legal & Compliance Officer and Corp. Sec.

Mr. Nathan Minnich
Sr. VP of Marketing

Mr. Daniel E. Owens (Age 51)
Chief HR Officer

Mr. Jaime A. Frias (Age 61)
Chief Bus. Devel. Officer

Dr. Sean F. Scanlan Ph.D. (Age 40)
Chief Innovation Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TMCI Stock - Frequently Asked Questions

Should I buy or sell Treace Medical Concepts stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TMCI shares.
View TMCI analyst ratings or view top-rated stocks.
What is Treace Medical Concepts' stock price forecast for 2023?: 5 Wall Street research analysts have issued 12-month price objectives for Treace Medical Concepts' shares. Their TMCI share price forecasts range from $24.00 to $30.00. On average, they anticipate the company's stock price to reach $27.30 in the next year. This suggests a possible upside of 108.2% from the stock's current price.
View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts.
How have TMCI shares performed in 2023?: Treace Medical Concepts' stock was trading at $22.99 on January 1st, 2023. Since then, TMCI shares have decreased by 43.0% and is now trading at $13.11.
View the best growth stocks for 2023 here.
Are investors shorting Treace Medical Concepts?: Treace Medical Concepts saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,660,000 shares, an increase of 28.7% from the August 31st total of 1,290,000 shares. Based on an average daily volume of 468,100 shares, the days-to-cover ratio is currently 3.5 days. Approximately 3.8% of the company's shares are short sold.
View Treace Medical Concepts' Short Interest.
When is Treace Medical Concepts' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our TMCI earnings forecast.
How were Treace Medical Concepts' earnings last quarter?: Treace Medical Concepts, Inc. (NASDAQ:TMCI) released its earnings results on Tuesday, August, 8th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. The business earned $41.95 million during the quarter, compared to the consensus estimate of $40.84 million. Treace Medical Concepts had a negative net margin of 25.32% and a negative trailing twelve-month return on equity of 39.29%. The company's revenue for the quarter was up 40.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.23) EPS.

What guidance has Treace Medical Concepts issued on next quarter's earnings?: Treace Medical Concepts updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $191.00 million-$197.00 million, compared to the consensus revenue estimate of $194.06 million.
When did Treace Medical Concepts IPO?: (TMCI) raised $150 million in an IPO on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.
What is Treace Medical Concepts' stock symbol?: Treace Medical Concepts trades on the NASDAQ under the ticker symbol "TMCI."
How do I buy shares of Treace Medical Concepts?: Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Treace Medical Concepts' stock price today?: One share of TMCI stock can currently be purchased for approximately $13.11.
How much money does Treace Medical Concepts make?: Treace Medical Concepts (NASDAQ:TMCI) has a market capitalization of $806.79 million and generates $141.84 million in revenue each year. The company earns $-42,810,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis.
How many employees does Treace Medical Concepts have?: The company employs 423 workers across the globe.
How can I contact Treace Medical Concepts?: Treace Medical Concepts' mailing address is 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081. The official website for the company is www.treace.com. The company can be reached via phone at 904-373-5940 or via email at ir@treace.net.

This page (NASDAQ:TMCI) was last updated on 9/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial